Georgiamune

Georgiamune, based in Gaithersburg, the United States, is a biotechnology company. Georgiamune develops immunotherapies that reprogram immune signalling pathways to rebalance immune system components, for cancer and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GIM122 and GIM-531 in melanoma. The largest, NCT06425926 (Safety and Tolerability Study of GIM-531 in Advanced Solid Tumours), plans to enrol 117 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.